← Leaderboards
Raymond Wenhou Zhou
Glytr Therapeutics, Inc.
$1,628,029
Attributed
$3,256,058
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,256,058 · 3
By mechanism
R42$2,857,880 · 2
R41$398,178 · 1
Top collaborators
- Michael Demetriou5 shared
Others in their field
Other Emerging Leaders on “New Technology”
- Leonard Freedman · Leidos Biomedical Research, Inc.$301,078,071
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Joel A Lipkin · Four Points Technology, Llc$181,896,915
- Lynn Briscoe · Leidos Biomedical Research, Inc.$116,337,613
- Terry Drinkwine · Carahsoft Technology Corporation$91,908,563
- Peter K Fritschel · California Institute Of Technology$78,820,000
Research focus
New TechnologySolidImmunotherapyMalignant NeoplasmsPolysaccharidesSafetyCell SurfaceImmuneIn VivoLectinImmune SystemNormal Tissue MorphologyPreclinical DevelopmentProteinsAntibodiesCarbohydratesCellsCancer CellCell Surface ProteinsIn VitroCancer ImmunotherapyBindingAntigensT-Lymphocyte
Grant awards (5)
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy$1,085,460
R42 · FY2025 · CA
Maximizing GlyTR pan-cancer immunotherapy by enhancing target density$463,510
R42 · FY2025 · CA
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy$908,910
R42 · FY2024 · CA
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy$400,000
R42 · FY2023 · CA
Cancer Immunotherapy Targeting Tn Antigen$398,178
R41 · FY2021 · CA